<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/98CA30BF-30DB-4DF3-BA70-43BBC5E16234"><gtr:id>98CA30BF-30DB-4DF3-BA70-43BBC5E16234</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:surname>Keilkowska</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F000L0786"><gtr:id>D8C4C878-519F-4B2E-847F-2028B7B2E0CA</gtr:id><gtr:title>The role of PtdIns(3,4)P2 in neutrophil signalling</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/000L0786</gtr:grantReference><gtr:abstractText>PI(4,5)P2 is a phosphoinositide found in all eukaryotic cells. It is a substrate for two central, but independent, signalling pathways, the PLCs, that make DAG and Ins(1,4,5)P3, and the class I PI3Ks, that make PIP3, it is also thought to serve roles as a plasma membrane-targetting motif for a number of proteins. PI(4,5)P2 seems to fulfil this range of roles by existing in discrete &amp;quot;pools&amp;quot; within the plasma or internal membranes that sub-serve different aspects of its full function. How these discrete pools are maintained and regulated is far from understood but crucial to the signalling by both PIP3 and DAG/Ins(1,4,5)P3. The levels of PI(4,5)P2 are regulated tightly and are maintained in the face of either huge changes in its rate of consumption by PLCs and/or PI3Ks or other longer-term &amp;quot;metabolic&amp;quot; perturbations potentially impacting phospholipid synthesis more broadly. This is clear evidence that the enzymes making and breaking down PI(4,5)P2 are subject to important and sophisticated control. PI(4,5)P2 is mainly synthesised by a family of type I &amp;quot;PIPkinases&amp;quot; (and which has 3 splice variants). A large family of 5-phosphataes are thought to be the main route by which PI(4,5)P2 can be degraded without generating PLC or PI3K signals. Hence a plausible model to explain PI(4,5)P2 biology is that discrete pools of PI(4,5)P2, in the plasma or internal membranes and that can co-exist in the same cell membrane, are based upon cassettes of specific isoforms and/or splice variants of the PIPkinases and PI(4,5)P2 phosphatases. One of these pools may support PIP3 production.</gtr:abstractText><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2013-10-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>81894</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/000L0786</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>